HERTFORDSHIRE, England and PITTSBURGH, June 18, 2015 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL) today commented on the ruling by the U.S. Court of Appeals for the Federal Circuit, which again has found Teva's U.S. Patent No. 5,800,808 ("the '808 patent") for Copaxone® to be invalid as indefinite.  

Mylan CEO Heather Bresch said, "We have stated all along that the '808 patent on Copaxone® is invalid and are gratified that the Federal Circuit Court of Appeals has agreed and put this matter to rest. We continue to remain very confident in our application for our generic version of Copaxone and look forward to bringing our product to market upon approval from the U.S. Food and Drug Administration.

"Further, we believe this ruling underscores concerns with Teva's ongoing financial prospects, as Teva's Copaxone franchise has historically been its largest and most significant revenue driver."

This press release includes statements that constitute "forward-looking statements," including with regard to litigation, product approvals and sales of products. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; uncertainties and other matters beyond the control of management; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which nearly 50% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. Our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/us-court-of-appeals-for-the-federal-circuit-finds-tevas-808-copaxone-patent-invalid-300101464.html

SOURCE Mylan N.V.